The role of cytology specimens in molecular testing of solid tumors: Techniques, limitations, and opportunities

Diagnostic Cytopathology

Volumn 40, Issue 6, 2012, Pages 511-524

  Aisner, Dara L ^a   Sams, Sharon B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

cytology; FISH; molecular; personalized medicine; testing

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROTEIN P53;

ANALYTIC METHOD; ASPIRATION BIOPSY; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME ABERRATION; CONFERENCE PAPER; CRYOPRESERVATION; CYTOPATHOLOGY; DISSECTION; DNA DEGRADATION; FLUORESCENCE IN SITU HYBRIDIZATION; FORMALIN FIXED PARAFFIN EMBEDDED SPECIMEN; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; MACRODISSECTION; MICRODISSECTION; MOLECULAR PATHOLOGY; MULTIPLEX POLYMERASE CHAIN REACTION; PREANALYTICAL PROCESSING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILVER ENHANCED IN SITU HYBRIDIZATION; SOLID TUMOR;

BIOPSY, FINE-NEEDLE; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; GENOME, HUMAN; HUMANS; INTERDISCIPLINARY COMMUNICATION; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TISSUE FIXATION;

EID: 84861535215     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22820     Document Type: Conference Paper

References (122)

1. Tsongalis GJ, Silverman LM,. Molecular diagnostics: A historical perspective. Clin Chim Acta; Int J Clin Chem 2006; 369: 188-192.
2. Nilsson G, Wang M, Wejde J, et al. Reverse transcriptase polymerase chain reaction on fine needle aspirates for rapid detection of translocations in synovial sarcoma. Acta Cytol 1998; 42: 1317-1324.
3. Kilpatrick SE, Cappellari JO, Bos GD, Gold SH, Ward WG,. Is fine-needle aspiration biopsy a practical alternative to open biopsy for the primary diagnosis of sarcoma? Experience with 140 patients. Am J Clin Pathol 2001; 115: 59-68.
4. Sapi Z, Antal I, Papai Z, et al. Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques. Diagn Cytopathol 2002; 26: 232-242.
5. Singh HK, Kilpatrick SE, Silverman JF,. Fine needle aspiration biopsy of soft tissue sarcomas: Utility and diagnostic challenges. Adv Anat Pathol 2004; 11: 24-37.
6. Schmitt FC,. Demystifying molecular cytopathology. Int J Surg Pathol 2010; 18 (3 Suppl): 213S-215S.
7. Krishnamurthy S,. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer 2007; 111: 106-122.
8. Clark DP,. Seize the opportunity: Underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer 2009; 117: 289-297.
9. Jennings L, Van Deerlin VM, Gulley ML,. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 2009; 133: 743-755.
10. Saah AJ, Hoover DR,. "Sensitivity" and "specificity" reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Int Med 1997; 126: 91-94.
11. Pao W, Ladanyi M,. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. Clin Cancer Res: An Official Journal of the American Association for Cancer Research 2007; 13: 4954-4955.
12. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN,. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009; 133: 1600-1606.
13. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G,. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: A review. Diagn Cytopathol 2011; 39: 703-710.
14. Lim EH, Zhang SL, Li JL, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2009; 4: 12-21.
15. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI,. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009; 117: 67-72.
16. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Investig 2006; 116: 2695-2706.
17. Dote H, Tsukuda K, Toyooka S, Yano M, Pass HI, Shimizu N,. Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP. Oncol Reports 2004; 11: 361-363.
18. Frantz C, Sekora DM, Henley DC, et al. Comparative evaluation of three JAK2V617F mutation detection methods. Am J Clin Pathol 2007; 128: 865-874.
19. Kawada I, Soejima K, Watanabe H, et al. An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2008; 3: 1096-1103.
20. Pan Q, Pao W, Ladanyi M,. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005; 7: 396-403.
21. Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: Comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 2000; 46: 1929-1938.
22. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA,. KRAS mutation: Comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010; 12: 43-50.
23. Weidlich S, Walsh K, Crowther D, et al. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer 2011; 105: 246-254.
24. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F,. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011; 30: 57.
25. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 413-421.
26. Carbonell P, Turpin MC, Torres-Moreno D, et al. Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. J Mol Diagn 2011; 13: 467-473.
27. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009; 11: 140-147.
28. Su Z, Dias-Santagata D, Duke M, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011; 13: 74-84.
29. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010; 2: 146-158.
30. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011; 13: 504-513.
31. Elliott K, Hamilton PW, Maxwell P,. Fluorescence (FISH) and chromogenic (CISH) in situ hybridisation in prostate carcinoma cell lines: Comparison and use of virtual microscopy. Br J Biomed Sci 2008; 65: 167-171.
32. Garcia-Caballero T, Grabau D, Green AR, et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens. Histopathology 2010; 56: 472-480.
33. Arena V, Pennacchia I, Vecchio FM, Carbone A,. "CISH the FISH" for HER2: Our laboratory experience. Am J Clin Pathol 2010; 134: 347-348.
34. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: Fluorescence in situ hybridization. Genetics in Medicine: Official Journal of the American College of Medical Genetics 2011; 13: 667-675.
35. Greer CE, Peterson SL, Kiviat NB, Manos MM,. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 1991; 95: 117-124.
36. Hunt JL,. Molecular pathology in anatomic pathology practice: A review of basic principles. Arch Pathol Lab Med 2008; 132: 248-260.
37. Hunt JL, Finkelstein SD,. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med 2004; 128: 1372-1378.
38. Troncone G, Malapelle U, Cozzolino I, Palombini L,. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010; 38: 869-873.
39. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: A sensitive method for molecular diagnosis. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2007; 2: 1086-1090.
40. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M,. EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens. Cancer Cytopathol 2011; 119: 111-117.
41. Umudum H, Rezanko T, Dag F, Dogruluk T,. Human papillomavirus genome detection by in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. Cancer 2005; 105: 171-177.
42. Zhang MQ, El-Mofty SK, Davila RM,. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: A tool for identifying the site of an occult head and neck primary. Cancer 2008; 114: 118-123.
43. Sviatoha V, Tani E, Ghaderi M, Kleina R, Skoog L,. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. Anticancer Res 2010; 30: 3267-3272.
44. Hookim K, Roh MH, Willman J, et al. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer Cytopathol 2011. DOI: 10.1002/cncy. 20180.
45. Apple SK, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL, Grody WW,. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 1996; 105: 321-326.
46. Rader AE, Avery A, Wait CL, McGreevey LS, Faigel D, Heinrich MC,. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. Cancer 2001; 93: 269-275.
47. Schenk T, Ackermann J, Brunner C, et al. Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Chest 1997; 111: 1691-1696.
48. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. International Journal of Cancer. Journal International du Cancer 2006; 118: 963-969.
49. Willmore-Payne C, Layfield LJ, Holden JA,. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Cancer 2005; 105: 165-170.
50. Abati A, Sanjuan X, Wilder A, Linehan WM, Hewitt SM, Merino MJ,. Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. Cancer 1999; 87: 231-237.
51. Beaty MW, Zhuang Z, Park WS, et al. Fine-needle aspiration of metastatic clear cell carcinoma of the kidney: Employment of microdissection and the polymerase chain reaction as a potential diagnostic tool. Cancer 1997; 81: 180-186.
52. Bozzetti C, Nizzoli R, Guazzi A, et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2002; 13: 1398-1403.
53. Kapila K, Al-Awadhi S, Francis I,. Her-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry. Journal of Cytology/Indian Academy of Cytologists 2011; 28: 54-56.
54. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: Fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 2004; 122: 246-255.
55. Arentsen HC, de la Rosette JJ, de Reijke TM, Langbein S,. Fluorescence in situ hybridization: A multitarget approach in diagnosis and management of urothelial cancer. Exp Rev Mol Diagn 2007; 7: 11-19.
56. Halling KC, Kipp BR,. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 2008; 15: 279-286.
57. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006; 176: 44-47.
58. Dillon DA, Johnson CC, Topazian MD, Tallini G, Rimm DL, Costa JC,. The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma. Cancer J 2000; 6: 294-301.
59. Fritcher EG, Halling KC,. Advanced cytologic approaches for the diagnosis of pancreatobiliary cancer. Curr Opin Gastroenterol 2010; 26: 259-264.
60. Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH, Jett JR,. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 2006; 130: 694-701.
61. Keohavong P, Gao WM, Zheng KC, et al. Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal Biochem 2004; 324: 92-99.
62. Khalid A, Pal R, Sasatomi E, et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut 2004; 53: 1860-1865.
63. Voss JS, Kipp BR, Halling KC, et al. Fluorescence in situ hybridization testing algorithm improves lung cancer detection in bronchial brushing specimens. Am J Resp Crit Care Med 2010; 181: 478-485.
64. Van Laethem JL, Bourgeois V, Parma J, et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest Endosc 1998; 47: 479-485.
65. Barr Fritcher EG, Caudill JL, Blue JE, et al. Identification of malignant cytologic criteria in pancreatobiliary brushings with corresponding positive fluorescence in situ hybridization results. Am J Clin Pathol 2011; 136: 442-449.
66. Willmore-Payne C, Volmar KE, Huening MA, Holden JA, Layfield LJ,. Molecular diagnostic testing as an adjunct to morphologic evaluation of pancreatic ductal system brushings: Potential augmentation for diagnostic sensitivity. Diagn Cytopathol 2007; 35: 218-224.
67. Sokolova IA, Bubendorf L, O'Hare A, et al. A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer 2002; 96: 306-315.
68. Yamaguchi K, Nakano K, Nagai E, et al. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. Hepato-gastroenterology 2005; 52: 713-718.
69. Yamashita K, Kuba T, Shinoda H, Takahashi E, Okayasu I,. Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 1998; 109: 704-711.
70. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, Yang CT,. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J 2006; 29: 373-379.
71. Jian G, Songwen Z, Ling Z, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 1341-1347.
72. Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006; 95: 1390-1395.
73. Fiegl M, Massoner A, Haun M, et al. Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer 2004; 91: 558-563.
74. Fiegl M, Kaufmann H, Zojer N, et al. Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol 2000; 31: 448-455.
75. Zojer N, Fiegl M, Angerler J, et al. Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients. Br J Cancer 1997; 75: 403-407.
76. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010; 138: 137-144.
77. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 2010; 63: 630-634.
78. Stancel GA, Coffey D, Alvarez K, et al. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay. Cancer cytopathology 2011.
79. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369.
80. Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010; 95: 5296-5304.
81. Dillon DA, Hipolito E, Zheng K, Rimm DL, Costa JC,. p53 mutations as tumor markers in fine needle aspirates of palpable breast masses. Acta Cytol 2002; 46: 841-847.
82. Hubbard RA,. Human papillomavirus testing methods. Arch Pathol Lab Med 2003; 127: 940-945.
83. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098.
84. Nishino HT, Tambouret RH, Wilbur DC,. Testing for human papillomavirus in cervical cancer screening: A review of indications and methodology. Cancer Cytopathol 2011; 119: 219-227.
85. Tisserand P, Fouquet C, Marck V, et al. ThinPrep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis: Application to p53 mutation analysis. Cancer 2003; 99: 223-232.
86. Kipp BR, Fritcher EG, Clayton AC, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn 2010; 12: 780-786.
87. Pugliese V, Pujic N, Saccomanno S, et al. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: Cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest Endosc 2001; 54: 595-599.
88. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011.
89. von Smolinski D, Leverkoehne I, von Samson-Himmelstjerna G, Gruber AD,. Impact of formalin-fixation and paraffin-embedding on the ratio between mRNA copy numbers of differently expressed genes. Histochem Cell Biol 2005; 124: 177-188.
90. Ladd AC, O'Sullivan-Mejia E, Lea T, et al. Preservation of fine-needle aspiration specimens for future use in RNA-based molecular testing. Cancer Cytopathol 2011; 119: 102-110.
91. Jiang F, Katz RL,. Use of interphase fluorescence in situ hybridization as a powerful diagnostic tool in cytology. Diagnostic Molecular Pathology: the American Journal of Surgical Pathology, Part B 2002; 11: 47-57.
92. Abati A, Sanford JS, Fetsch P, Marincola FM, Wolman SR,. Fluorescence in situ hybridization (FISH): A user's guide to optimal preparation of cytologic specimens. Diagn Cytopathol 1995; 13: 486-492.
93. da Cunha Santos G, Saieg MA, Geddie W, Leighl N,. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: Controversies and opportunities. Cancer Cytopathol 2011; 119: 80-91.
94. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms is non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451-458.
95. Srinivasan M, Sedmak D, Jewell S,. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002; 161: 1961-1971.
96. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999; 155: 1467-1471.
97. Ben-Ezra J, Johnson DA, Rossi J, Cook N, Wu A,. Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 1991; 39: 351-354.
98. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: Untapped resource for clinical molecular profiling. J Mol Diagn 2010; 12: 739-745.
99. Cajulis RS, Frias-Hidvegi D, Yu GH, Eggena S,. Detection of numerical chromosomal abnormalities by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes on archival cytologic samples. Diagn Cytopathol 1996; 14: 178-181.
100. Nizzoli R, Guazzi A, Naldi N, Fraciosi V, Bozzetti C,. HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer. Acta Cytol 2005; 49: 27-30.
101. Bozzetti C, Personeni N, Nizzoli R, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003; 99: 310-315.
102. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. The Oncologist 2008; 13: 1270-1275.
103. Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: Discordance in pleural metastases. Clin Lung Cancer 2011.
104. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99: 923-929.
105. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2008; 3: 18-22.
106. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: Implications for treatment with EGFR-inhibitors. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2006; 17: 981-985.
107. Italiano A, Saint-Paul MC, Caroli-Bosc FX, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: Biological and clinical implications. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2005; 16: 1503-1507.
108. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-1026.
109. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2008; 3: 331-339.
110. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology 2009; 20: 298-304.
111. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
112. Akbari M, Hansen MD, Halgunset J, Skorpen F, Krokan HE,. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn 2005; 7: 36-39.
113. Brevet M, Arcila M, Ladanyi M,. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010; 12: 169-176.
114. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010; 16: 1561-1571.
115. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19.
116. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009; 15: 3023-3028.
117. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2011; 6: 459-465.
118. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009; 40: 1152-1158.
119. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011; 17: 1169-1180.
120. Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010; 10: 101.
121. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLOS One 2010; 5: e8802.
122. da Cunha Santos G, Liu N, Tsao MS, Kamel-Reid S, Chin K, Geddie WR,. Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: Is this the tool for biobanking cytological samples in the molecular era? Cancer Cytopathol 2010; 118: 450-456.